----

----

----

| Delaware                                                                                    |            | 26-4333375                                                                          |
|---------------------------------------------------------------------------------------------|-----------------|-------------------------------------------------------------------------------------|
| (State or other jurisdiction of incorporationor organization) |            | (IRS Employer Identification No.)                                    |
|                                                                                        |            |                                                                                |
| 12424 Wilshire Blvd, Suite 745Los Angeles, CA                                               | 90025           | (512) 329-2643                                                                      |
| (Address of principal executive office)                                 | (Zip Code) | (Registrant’s telephone number, Including area code) |

| Large accelerated filer | ☐ |   | Accelerated filer         | ☐ |
|-------------------------|---------|--------|---------------------------|---------|
| Non-accelerated filer   | ☐ |   | Smaller reporting company | ☒ |
| Emerging growth company | ☒ |   |                      |    |

----

----

|     |   |                                                                                                               |   | PAGE             |   |
|----------|--------|--------------------------------------------------------------------------------------------------------------------|--------|------------------|--------|
| PART I   |   |
|     |   |                                                                                                               |   |
| Item 1.  |   | Business                                                                                                           |   | 3                |   |
| Item 1A. |   | Risk Factors                                                                                                       |   | 19               |   |
| Item 1B. |   | Unresolved Staff Comments                                                                                          |   | 36               |   |
| Item 2.  |   | Properties                                                                                                         |   | 36               |   |
| Item 3.  |   | Legal Proceedings                                                                                                  |   | 36               |   |
| Item 4.  |   | Mine Safety Disclosures                                                                                            |   | 36               |   |
|     |   |                                                                                                               |   |             |   |
| PART II  |   |
|     |   |                                                                                                               |   |
| Item 5.  |   | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities |   | 37               |   |
| Item 6.  |   | Selected Financial Data                                                                                            |   | 37               |   |
| Item 7.  |   | Management’s Discussion and Analysis of Financial Condition and Results of Operations                        |   | 38               |   |
| Item 7A. |   | Quantitative and Qualitative Disclosures about Market Risk                                                         |   | 43               |   |
| Item 8.  |   | Financial Statements and Supplementary Data                                                                        |   | F-1 – F-34 |   |
| Item 9.  |   | Changes in and Disagreements with Accountants on Accounting and Financial Disclosures                              |   | 44               |   |
| Item 9A. |   | Controls and Procedures                                                                                            |   | 44               |   |
| Item 9B. |   | Other Information                                                                                                  |   | 45               |   |
|     |   |                                                                                                               |   |             |   |
| PART III |   |
|     |   |                                                                                                               |   |
| Item 10. |   | Directors, Executive Officers and Corporate Governance                                                             |   | 46               |   |
| Item 11. |   | Executive Compensation                                                                                             |   | 50               |   |
| Item 12. |   | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters                     |   | 54               |   |
| Item 13. |   | Certain Relationships and Related Transactions, and Director Independence                                          |   | 57               |   |
| Item 14. |   | Principal Accounting Fees and Services                                                                             |   | 57               |   |
|     |   |                                                                                                               |   |             |   |
| PART IV  |   |
|     |   |                                                                                                               |   |
| Item 15. |   | Exhibits, Financial Statement Schedules                                                                            |   | 59               |   |
| Item 16. |   | Form 10-K Summary                                                                                                  |   | 63               |   |
|     |   |                                                                                                               |   |             |   |
|     |   | Signatures                                                                                                         |   | 64               |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

| ● | Precise, uninterrupted, real-time evaluations of electrograms (PURE EPTM); |
|---------|---------------------------------------------------------------------------------|

| ● | Higher quality cardiac signal acquisition for accurate and more efficient electrophysiology studies and catheter ablation procedures to help reduce costs and length of procedures; |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | Reliable display of information to better determine precise ablation targets, strategy and end point of procedures with the objective of reducing the need for multiple procedures; |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | A device that can be fully integrated into existing electrophysiology lab environments. |
|---------|-----------------------------------------------------------------------------------------|

| ● | Initial system concept validation has been performed in collaboration with physicians at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas in June 2011.  The Texas Cardiac Arrhythmia Institute provided challenging recordings obtained with electrophysiology recording systems presently in use at the institute during various electrophysiology studies. Our technology team successfully imported the data into the PURE EP System software and using proprietary signal processing, the PURE EP System software was able to reduce baseline wander, noise, and artifacts from the data and therefore provide better diagnostic quality signals. |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | We have established clinical and/or advisory relationships for both technology development and validation studies with physicians and researchers affiliated with the following medical centers: Texas Cardiac Arrhythmia Institute, Austin, TX; Cardiac Arrhythmia Center at the University of California at Los Angeles, Los Angeles, CA; Mount Sinai Medical Center, New York, NY; Beaumont Medical Center, Detroit, MI; University Hospitals Case Medical Center, Cleveland, OH; The Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK; and Mayo Clinic, Rochester, MN. |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | The Cardiac Arrhythmia Center at the University of California at Los Angeles and Dr. Kalyanam Shivkumar, a former member of our board of directors, have played a significant role in the initial functional testing of our hardware.  Dr. Shivkumar and his team have enabled us to learn the connectivity of the lab and its devices that pertain to where our PURE EP System will fit in. In June 2013, we commenced our first proof of concept pre-clinical study with the assistance of Dr. Shivkumar in order to further test the components of the PURE EP System hardware, as further explained below. |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | We are developing signal processing tools within the PURE EP System that will assist electrophysiologists in further differentiating true signals from noise, which may potentially provide guidance in identifying ablation targets.  The signal processing tools are expected to be an integral part of the software of the PURE EP System, which we believe will significantly facilitate the locating of ablation targets. |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ● | In the second and third quarters of 2013, we performed and finalized testing of our proof of concept unit by initially using an electrocardiogram/intracardiac simulator at our lab, and subsequently by obtaining pre-clinical recordings from the lab at the University of California at Los Angeles.  As part of the testing, we simultaneously recorded electrocardiogram and intracardiac signals on our proof of concept unit and GE’s CardioLab recording system. An identical signal was applied to the input of both systems and the monitor of our proof of concept unit was positioned next to the monitor of GE’s CardioLab recording system to allow for visual comparison. We believe that our proof of concept unit performed well as compared to GE’s CardioLab recording system, in that the electrocardiogram and intracardiac signals displayed on our proof of concept unit showed less baseline wander, noise and artifacts compared to signals displayed on GE’s CardioLab recording system.  However, because this was a proof of concept test, without any clearly established protocols, we cannot present this data for publication and we do not have any independent verification or peer review of these findings. |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | In the third quarter of 2013, we analyzed the results of our proof of concept unit to determine the final design of the PURE EP System prototype, which has since been completed.   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | In September 2014, we performed additional tests on the PURE EP System prototype at the University of California at Los Angeles.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------|

| ● | In the fourth quarter of 2014, we appointed Dr. Samuel J. Asirvatham from Mayo Clinic as a member of our Scientific Advisory Board and initiated plans for pre-clinical studies at Mayo Clinic. |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | In the first quarter of 2015, we appointed Dr. K. L. Venkatachalam from Mayo Clinic, Jacksonville, Florida, as a member of our Scientific Advisory Board.  On March 31, 2015 Drs. Asirvatham and Venkatachalam performed our first pre-clinical study at the Mayo Clinic in Rochester, Minnesota. |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On June 10, 2015, Dr. Asirvatham performed our second pre-clinical study at Mayo Clinic in Rochester, Minnesota. |
|---------|------------------------------------------------------------------------------------------------------------------|

| ● | On November 17, 2015, Dr. Asirvatham performed our third pre-clinical study at Mayo Clinic in Rochester, Minnesota. |
|---------|---------------------------------------------------------------------------------------------------------------------|

| ● | On February 22, 2016, we signed an agreement to initiate development of its PURE EP System with Minnetronix and are taking steps toward its 510(k) submission. |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On March 8, 2016, Dr. Ammar Killu from Mayo Clinic presented our preclinical data at the 13th Annual Dead Sea Symposium on Innovations in Cardiac Arrhythmias and Device Therapy in Tel Aviv, Israel entitled “Enhanced Electrophysiology Recording Improves Signal Acquisition and Differentiation”. |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On March 28, 2016, we announced an Advanced Research Program with Dr. Asirvatham at the Mayo Clinic beginning June 2016. |
|---------|--------------------------------------------------------------------------------------------------------------------------|

| ● | On June 2, 2016, Dr. Asirvatham performed our fourth pre-clinical study at Mayo Clinic in Rochester, Minnesota. |
|---------|-----------------------------------------------------------------------------------------------------------------|

| ● | On June 23 and August 25 and 26, 2016, Dr. Vivek Reddy performed our pre-clinical study on a ventricular scar model at the Mount Sinai Hospital in New York, NY. |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On July 27, 2016, Dr. Asirvatham performed our fifth pre-clinical study at Mayo Clinic in Rochester, Minnesota. |
|---------|-----------------------------------------------------------------------------------------------------------------|

| ● | On August 19, 2016, we presented a poster at the IEEE Engineering in Medicine and Biology Society annual conference (IEEE EMBC 2016) entitled “Enhanced Electrophysiology Recording System.” |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On September 14, 2016, Dr. Asirvatham performed our sixth pre-clinical study at Mayo Clinic in Rochester, Minnesota. |
|---------|----------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ● | In December 2016, the Journal of the American College of Cardiology (JACC): Clinical Electrophysiology (Vol.2, No.7, pp.850) published the article entitled, “Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-Frequency Signals”, submitted by the Mayo Clinic team. |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On December 9, 2016, we filed a provisional patent application entitled “Assessment of Catheter Position by Local Electrogram.” |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On December 9, 2016, we filed a provisional patent application entitled “Visualization of Conduction Tissue Signals.” |
|---------|-----------------------------------------------------------------------------------------------------------------------------------|

| ● | On February 14, 2017, Dr. Asirvatham performed our seventh pre-clinical study at Mayo Clinic in Rochester, Minnesota. |
|---------|-----------------------------------------------------------------------------------------------------------------------|

| ● | On March 15, 2017, Dr. Asirvatham performed our eighth pre-clinical study at Mayo Clinic in Rochester, Minnesota. |
|---------|-------------------------------------------------------------------------------------------------------------------|

| ● | In April 2017, the PURE EP System was featured in The Journal of Innovations in Cardiac Rhythm Management with the manuscript entitled, “Initial Experience with the BioSig PURE EPTM Signal Recording System: An Animal Laboratory Experience” co-authored by physicians from Mayo Clinic and Harvard Brigham & Women’s Hospital. |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On May 2, 2017, Dr. Asirvatham performed our ninth pre-clinical study at Mayo Clinic in Rochester, Minnesota. |
|---------|---------------------------------------------------------------------------------------------------------------|

| ● | On May 11, 2017, the PURE EP System was featured in a poster presentation entitled, “Use of Terminal Unipolar Electrogram Current of Injury as a Novel Marker to Estimate Contact: An Acute Canine Study.” |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On May 31, we announced that we have appointed Natasha Russkina as a Managing Director, Europe with the view of establishing European operations of BioSig Technologies, Inc. in Geneva, Switzerland. |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On July 10, 2017, the PURE EP System was featured in a poster presentation at the American Heart Association’s 13th Annual Basic Cardiovascular Sciences (BCVS) 2017 Scientific Sessions: Pathways to Cardiovascular Therapeutics entitled, “Use of a Novel Electrogram Filtering Algorithm to Visualize Conduction Tissue Signals in the Ventricle in Sinus Rhythm and Arrhythmia: An Acute Canine Study.” |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On July 11, 2017, we announced that we have engaged Health Research International (HRI) to compile essential market data and help perform strategic planning for its PURE EPTM platform technology. |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On July 12, 2017, the PURE EP System was featured in a poster presentation at the American Heart Association’s 13th Annual Basic Cardiovascular Sciences (BCVS) 2017 Scientific Sessions: Pathways to Cardiovascular Therapeutics entitled, “Assessment of Catheter Position above or below the Aortic Valve by Evaluation of Characteristics of the Local Electro gram: An Acute Canine Study.” |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On August 9, 2017, Dr. Asirvatham performed our tenth pre-clinical study at Mayo Clinic in Rochester, Minnesota. |
|---------|------------------------------------------------------------------------------------------------------------------|

| ● | On October 11, 2017, we announced that Mr. Joseph W. Rafferty has joined the Company as Chief Commercialization Officer. |
|---------|--------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ● | On October 19, 2017, we announced that we have made significant progress towards commercialization of our PURE EP System and recently received the first production units of the PURE EP System from our manufacturing partner, Minnetronix. |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On October 24, 2017, we announced that we have engaged Quintain Project Solutions LLC as the manufacturing project management leader for the PURE EP System. |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On October 26, 2017, we announced that we concluded a key part of the strategic planning project launched earlier this year in collaboration with Health Research International (HRI). HRI conducted a detailed survey of U.S. electrophysiologists primarily based in New York, Texas, Massachusetts, Florida, Pennsylvania, and North Carolina to gather opinions on the main features of the PURE EP System. The inability to record high quality unipolar signals and difficulty detecting small intracardiac signals were consistently reported among the factors interfering with effective ablations. Survey respondents rated all six features listed of the PURE EP System as being ‘Very Helpful’ for their ablations, emphasizing overall noise reduction and improved signal clarity/accuracy as key benefits. Most respondents see signal clarity as paramount to the success of ablations and indicated interest in a technology that reduces ‘noise’. |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On November 2, 2017, we announced that we have engaged Sherpa Technology Group as our Intellectual Property Advisor. |
|---------|----------------------------------------------------------------------------------------------------------------------|

| ● | On November 10, 2017, we announced that Andrew Filler, Partner and General Counsel of Sherpa Technology Group has joined our board of directors taking the place of Dr. Jerome B. Zeldis. |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On November 14, 2017, we announced that we have added the role of Chief Regulatory and Compliance Officer in preparation of our FDA submission. |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On January 3, 2018 we announced that Steve Chaussy had been elevated to our full time Chief Financial Officer to facilitate growth trajectory of the Company. |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On January 9, 2018, we announced that we have partnered with Charles Austin and JK Advisors in preparation of the commercial launch of our PURE EP System. |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | On January 10, 2018, Dr. Asirvatham performed our eleventh pre-clinical study at Mayo Clinic in Rochester, Minnesota. |
|---------|-----------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| ● | GE Healthcare’s family of CardioLab Recording Systems were initially developed in the early 1990s by Prucka Engineering, which was acquired by General Electric Company in 1999.                                                            |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ● | The LabSystem PRO EP Recording System was originally designed in the late 1980s by C.R. Bard. C.R. Bard’s electrophysiology business was acquired by Boston Scientific Corporation in 2013.                                                 |
| ● | Siemens AG developed the Axiom Sensis XP in 2002.                                                                                                                                                                                                 |
| ● | St. Jude Medical, Inc.’s EP-WorkMate Recording System was acquired from EP MedSystems, Inc. in 2008, which had received clearance for the product from the FDA in 2003. In January 2017, Abbott Laboratories acquired St Jude Medical, Inc. |

----

Table of Contents

----

Table of Contents

| ● | Product design and development;              |
|---------|----------------------------------------------|
| ● | Product testing;                             |
| ● | Product manufacturing;                       |
| ● | Product labeling and packaging;              |
| ● | Product handling, storage, and installation; |
| ● | Pre-market clearance or approval;            |
| ● | Advertising and promotion; and               |
| ● | Product sales, distribution, and servicing.  |

----

Table of Contents

| ● | Quality System regulation, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures during the manufacturing process;                                                                                                                                   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ● | Establishment Registration, which requires establishments involved in the production and distribution of medical devices intended for commercial distribution in the U.S. to register with the U.S. Food and Drug Administration;                                                                                    |
| ● | Medical Device Listing, which requires manufacturers to list the devices they have in commercial distribution with the U.S. Food and Drug Administration;                                                                                                                                                            |
| ● | Labeling regulations, which prohibit “misbranded” devices from entering the market, as well as prohibit the promotion of products for unapproved or “off-label” uses and impose other restrictions on labeling; and                                                                          |
| ● | Medical Device Reporting regulations, which require that manufacturers report to the U.S. Food and Drug Administration if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur. |

| ● | Fines, injunctions, and civil penalties;                                                  |
|---------|-------------------------------------------------------------------------------------------|
| ● | Mandatory recall or seizure of our products;                                              |
| ● | Administrative detention or banning of our products;                                      |
| ● | Operating restrictions, partial suspension or total shutdown of production;               |
| ● | Refusing our request for 510(k) clearance or pre-market approval of new product versions; |
| ● | Revocation of 510(k) clearance or pre-market approvals previously granted; and            |
| ● | Criminal penalties.                                                                       |

----

Table of Contents

----

Table of Contents

|   | ● | successful completion of the pre-clinical and clinical development of our products; |
|--------|---------|-------------------------------------------------------------------------------------|

|   | ● | obtaining necessary regulatory approvals from the U.S. Food and Drug Administration or other regulatory authorities; |
|--------|---------|----------------------------------------------------------------------------------------------------------------------|

|   | ● | establishing manufacturing, sales, and marketing arrangements, either alone or with third parties; and |
|--------|---------|--------------------------------------------------------------------------------------------------------|

|   | ● | raising sufficient funds to finance our activities. |
|--------|---------|-----------------------------------------------------|

----

Table of Contents

| ● | the U.S. Food and Drug Administration may not approve a clinical trial protocol or a clinical trial, or may place a clinical trial on hold; |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------|

| ● | subjects may not enroll in clinical trials at the rate we expect or we may not follow up on subjects at the rate we expect; |
|---------|-----------------------------------------------------------------------------------------------------------------------------|

| ● | subjects may experience events unrelated to our products; |
|---------|-----------------------------------------------------------|

----

Table of Contents

| ● | third-party clinical investigators may not perform our clinical trials consistent with our anticipated schedule or the clinical trial protocol and good clinical practices, or other third-party organizations may not perform data collection and analysis in a timely or accurate manner; |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | interim results of any of our clinical trials may be inconclusive or negative; |
|---------|--------------------------------------------------------------------------------|

| ● | regulatory inspections of our clinical trials may require us to undertake corrective action or suspend or terminate the clinical trials if investigators find us not to be in compliance with regulatory requirements; or |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | governmental regulations or administrative actions may change and impose new requirements, particularly with respect to reimbursement. |
|---------|----------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ● | restrictions on our products, manufacturers or manufacturing processes; |
|---------|-------------------------------------------------------------------------|

| ● | warning letters and untitled letters; |
|---------|---------------------------------------|

| ● | civil penalties and criminal prosecutions and penalties; |
|---------|----------------------------------------------------------|

| ● | fines; |
|---------|--------|

| ● | injunctions; |
|---------|--------------|

| ● | product seizures or detentions; |
|---------|---------------------------------|

| ● | import or export bans or restrictions; |
|---------|----------------------------------------|

| ● | voluntary or mandatory product recalls and related publicity requirements; |
|---------|----------------------------------------------------------------------------|

| ● | suspension or withdrawal of regulatory approvals; |
|---------|---------------------------------------------------|

| ● | total or partial suspension of production; and |
|---------|------------------------------------------------|

| ● | refusal to approve pending applications for marketing approval of new products or of supplements to approved applications. |
|---------|----------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

| ● | we may not be able to attract and build an effective marketing or sales force; |
|---------|--------------------------------------------------------------------------------|

----

Table of Contents

| ● | the cost of establishing, training and providing regulatory oversight for a marketing or sales force may be substantial; and |
|---------|------------------------------------------------------------------------------------------------------------------------------|

| ● | there are significant legal and regulatory risks in medical device marketing and sales that we have never faced, and any failure to comply with applicable legal and regulatory requirements for sales, marketing and distribution could result in an enforcement action by the U.S. Food and Drug Administration, European regulators or other authorities that could jeopardize our ability to market our planned products or could subject us to substantial liability. |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

| ● | the degree and range of protection any patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents; |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | if and when such patents will be issued, and, if granted, whether patents will be challenged and held invalid or unenforceable; |
|---------|---------------------------------------------------------------------------------------------------------------------------------|

| ● | whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or |
|---------|--------------------------------------------------------------------------------------------------------------------------------|

| ● | whether we will need to initiate litigation or administrative proceedings which may be costly regardless of outcome. |
|---------|----------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ● | obtain licenses, which may not be available on commercially reasonable terms, if at all; |
|---------|------------------------------------------------------------------------------------------|

| ● | abandon an infringing product candidate; |
|---------|------------------------------------------|

| ● | redesign our product candidates or processes to avoid infringement; |
|---------|---------------------------------------------------------------------|

| ● | cease usage of the subject matter claimed in the patents held by others; |
|---------|--------------------------------------------------------------------------|

| ● | pay damages; and/or |
|---------|---------------------|

| ● | defend litigation or administrative proceedings which may be costly regardless of outcome, and which could result in a substantial diversion of our financial and management resources. |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ● | the outcomes of potential future patent litigation; |
|---------|-----------------------------------------------------|

| ● | our ability to monetize our future patents; |
|---------|---------------------------------------------|

| ● | changes in our industry; |
|---------|--------------------------|

| ● | announcements of technological innovations, new products or product enhancements by us or others; |
|---------|---------------------------------------------------------------------------------------------------|

| ● | announcements by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments; |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------|

| ● | changes in earnings estimates or recommendations by security analysts, if our common stock is covered by analysts; |
|---------|--------------------------------------------------------------------------------------------------------------------|

| ● | investors’ general perception of us; |
|---------|--------------------------------------------|

| ● | future issuances of common stock; |
|---------|-----------------------------------|

| ● | the addition or departure of key personnel; |
|---------|---------------------------------------------|

| ● | general market conditions, including the volatility of market prices for shares of technology companies, generally, and other factors, including factors unrelated to our operating performance; and |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | the other factors described in this “Risk Factors” section. |
|---------|-------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

| ● | incur additional indebtedness; |
|---------|--------------------------------|

| ● | permit liens on assets; |
|---------|-------------------------|

| ● | repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock; |
|---------|--------------------------------------------------------------------------------------------------|

| ● | pay cash dividends to our stockholders; and |
|---------|---------------------------------------------|

| ● | engage in transactions with affiliates. |
|---------|-----------------------------------------|

----

Table of Contents

----

Table of Contents

| Year Ending December 31, |   |   |    |
|--------------------------|--------|--------|---------|
| 2018                     |   | $      | 112,994 |   |
| 2019                     |   |   | 76,995  |   |
|                     |   | $      | 189,989 |   |

----

Table of Contents

|           |   | Fiscal Year 2017 |   |
|----------------|--------|------------------|--------|
|           |   | High             |   |   | Low |   |
| First Quarter  |   | $                | 2.00   |   |   | $ | 1.20 |   |
| Second Quarter |   | $                | 1.76   |   |   | $ | 1.23 |   |
| Third Quarter  |   | $                | 1.60   |   |   | $ | 1.25 |   |
| Fourth Quarter |   | $                | 1.75   |   |   | $ | 1.29 |   |

|           |   | Fiscal Year 2016 |   |
|----------------|--------|------------------|--------|
|           |   | High             |   |   | Low |   |
| First Quarter  |   | $                | 1.59   |   |   | $ | 0.90 |   |
| Second Quarter |   | $                | 2.15   |   |   | $ | 1.33 |   |
| Third Quarter  |   | $                | 1.60   |   |   | $ | 1.05 |   |
| Fourth Quarter |   | $                | 1.59   |   |   | $ | 1.25 |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

|                              |   | 2017   |      |   | 2016   |   |
|-----------------------------------|--------|--------|-----------|--------|--------|--------|
| Salaries and equity compensation  |   | $      | 1,481,421 |   |   | $      | 1,744,780 |   |
| Consulting expenses               |   |   | 500,628   |   |   |   | 322,520 |   |
| Clinical studies and design work  |   |   | 2,066,028 |   |   |   | 388,447 |   |
| Acquired research and development |   |   | 543,927   |   |   |   | - |   |
| Travel, supplies, other           |   |   | 164,464   |   |   |   | 198,754 |   |
|   Total                 |   | $      | 4,756,468 |   |   | $      | 2,654,501 |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Report of Independent Registered Public Accounting Firm                            | F-2 |
|------------------------------------------------------------------------------------|-----|
| Balance Sheets as of December 31, 2017 and 2016                                    | F-3 |
| Statements of Operations for the Years Ended December 31, 2017 and 2016            | F-4 |
| Statement of Stockholders’ Deficit for the two Years Ended December 31, 2017 | F-5 |
| Statements of Cash Flows for the Years Ended December 31, 2017 and 2016            | F-7 |
| Notes to Financial Statements                                                      | F-8 |

----

Table of Contents

----

Table of Contents

| BIOSIG TECHNOLOGIES, INC.                                                                                                                                                                        |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| BALANCE SHEETS                                                                                                                                                                                   |   |
| DECEMBER 31, 2017 AND 2016                                                                                                                                                                       |   |
|                                                                                                                                                                                             |   |   |   |   |   |   |
|                                                                                                                                                                                             |   | 2017 |   |   | 2016 |   |
| ASSETS                                                                                                                                                                                           |   |   |   |   |   |   |
| Current assets:                                                                                                                                                                                  |   |   |   |   |   |   |
| Cash                                                                                                                                                                                             |   | $ | 1,547,579 |   |   | $ | 1,055,895 |   |
| Prepaid expenses                                                                                                                                                                                 |   |   | 116,938 |   |   |   | 134,263 |   |
|   Total current assets                                                                                                                                                                 |   |   | 1,664,517 |   |   |   | 1,190,158 |   |
|                                                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Property and equipment, net                                                                                                                                                                      |   |   | 18,716 |   |   |   | 24,188 |   |
|                                                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Other assets:                                                                                                                                                                                    |   |   |   |   |   |   |   |   |
| Deposits                                                                                                                                                                                         |   |   | 17,084 |   |   |   | 27,612 |   |
|                                                                                                                                                                                             |   |   |   |   |   |   |   |   |
|   Total assets                                                                                                                                                                         |   | $ | 1,700,317 |   |   | $ | 1,241,958 |   |
|                                                                                                                                                                                             |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT                                                                                                                                                      |   |   |   |   |   |   |   |   |
| Current liabilities:                                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Accounts payable and accrued expenses, including $27,375 and $15,755 to related parties as of December 31, 2017 and 2016, respectively                                                           |   | $ | 473,098 |   |   | $ | 373,103 |   |
| Dividends payable                                                                                                                                                                                |   |   | 447,901 |   |   |   | 359,891 |   |
| Warrant liability                                                                                                                                                                                |   |   | 2,358,240 |   |   |   | 1,937,234 |   |
| Derivative liability                                                                                                                                                                             |   |   | 685,922 |   |   |   | 288,934 |   |
|   Total current  liabilities                                                                                                                                                      |   |   | 3,965,161 |   |   |   | 2,959,162 |   |
|                                                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Series C Preferred Stock, 985 and 1,070 shares issued and outstanding; liquidation preference of $985,000 and $1,070,000 as of December 31, 2017 and 2016, respectively                          |   |   | 985,000 |   |   |   | 1,070,000 |   |
|                                                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Stockholders’ deficit                                                                                                                                                                      |   |   |   |   |   |   |   |   |
| Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C and 1,400 shares of Series D Preferred Stock |   |   |   |   |   |   |   |   |
| Series D Preferred Stock, $0.001 par value, 1,334 and 0 shares issued and outstanding; liquidation preference of $2,001,000 and $0 as of December 31, 2017 and 2016, respectively                |   |   | 1 |   |   |   | - |   |
| Common stock, $0.001 par value, authorized 200,000,000 shares, 29,321,204 and 22,588,184 issued and outstanding as of December 31, 2017 and 2016, respectively                                   |   |   | 29,321 |   |   |   | 22,588 |   |
| Additional paid in capital                                                                                                                                                                       |   |   | 53,215,635 |   |   |   | 41,019,251 |   |
| Common stock subscription                                                                                                                                                                        |   |   | 29,985 |   |   |   | - |   |
| Accumulated deficit                                                                                                                                                                              |   |   | (56,524,786 | ) |   |   | (43,829,043 | ) |
|   Total stockholders’ deficit                                                                                                                                                    |   |   | (3,249,844 | ) |   |   | (2,787,204 | ) |
|                                                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Total liabilities and stockholders’ deficit                                                                                                                                                |   | $ | 1,700,317 |   |   | $ | 1,241,958 |   |

----

Table of Contents

| BIOSIG TECHNOLOGIES, INC.                                               |   |
|-------------------------------------------------------------------------|--------|
| STATEMENTS OF OPERATIONS                                                |   |
|                                                                    |   |   |   |   |   |   |
|                                                                    |   | Year ended December 31, |   |
|                                                                    |   | 2017 |   |   | 2016 |   |
| Operating expenses:                                                     |   |   |   |   |   |   |
| Research and development                                                |   | $ | 4,756,468 |   |   | $ | 2,654,501 |   |
| General and administrative                                              |   |   | 8,138,117 |   |   |   | 8,499,304 |   |
| Depreciation                                                            |   |   | 11,698 |   |   |   | 10,475 |   |
|   Total operating expenses                                    |   |   | 12,906,283 |   |   |   | 11,164,280 |   |
|                                                                    |   |   |   |   |   |   |   |   |
| Loss from operations                                                    |   |   | (12,906,283 | ) |   |   | (11,164,280 | ) |
|                                                                    |   |   |   |   |   |   |   |   |
| Other income (expense):                                                 |   |   |   |   |   |   |   |   |
| Gain (loss) on change in fair value of derivatives                      |   |   | 210,465 |   |   |   | (422,908 | ) |
| Interest income                                                         |   |   | 75 |   |   |   | 1 |   |
|                                                                    |   |   |   |   |   |   |   |   |
| Loss before income taxes                                                |   |   | (12,695,743 | ) |   |   | (11,587,187 | ) |
|                                                                    |   |   |   |   |   |   |   |   |
| Income taxes (benefit)                                                  |   |   | - |   |   |   | - |   |
|                                                                    |   |   |   |   |   |   |   |   |
| Net loss                                                                |   |   | (12,695,743 | ) |   |   | (11,587,187 | ) |
|                                                                    |   |   |   |   |   |   |   |   |
| Preferred stock dividend                                                |   |   | (119,877 | ) |   |   | (110,023 | ) |
|                                                                    |   |   |   |   |   |   |   |   |
| NET LOSS AVAILABLE TO COMMON STOCKHOLDERS                               |   | $ | (12,815,620 | ) |   | $ | (11,697,210 | ) |
|                                                                    |   |   |   |   |   |   |   |   |
| Net loss per common share, basic and diluted                            |   | $ | (0.50 | ) |   | $ | (0.60 | ) |
|                                                                    |   |   |   |   |   |   |   |   |
| Weighted average number of common shares outstanding, basic and diluted |   |   | 25,550,686 |   |   |   | 19,490,767 |   |

----

Table of Contents

| BIOSIG TECHNOLOGIES, INC.                                                                                            |   |
|----------------------------------------------------------------------------------------------------------------------|--------|
| CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT                                                                   |   |
| TWO YEARS ENDED DECEMBER 31, 2017                                                                                    |   |
|                                                                                                                 |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                                 |   |   |   |   |   |   |   |   |   |   |   |   |   | Additional |   |   | Common |   |   |   |   |   |   |   |
|                                                                                                                 |   | Series D Preferred stock |   |   | Common stock |   |   | Paid in |   |   | stock |   |   | Accumulated |   |   |   |   |
|                                                                                                                 |   | Shares |   |   | Amount |   |   | Shares |   |   | Amount |   |   | Capital |   |   | Subscription |   |   | Deficit |   |   | Total |   |
| Balance, January 1, 2016                                                                                             |   |   | - |   |   | $ | - |   |   |   | 16,825,703 |   |   | $ | 16,826 |   |   | $ | 29,314,399 |   |   | $ | - |   |   | $ | (32,241,856 | ) |   | $ | (2,910,631 | ) |
| Sale of common stock                                                                                                 |   |   | - |   |   |   | - |   |   |   | 3,798,417 |   |   |   | 3,798 |   |   |   | 5,222,570 |   |   |   | - |   |   |   | - |   |   |   | 5,226,368 |   |
| Common stock issued for services                                                                                     |   |   | - |   |   |   | - |   |   |   | 1,335,000 |   |   |   | 1,335 |   |   |   | 2,469,715 |   |   |   | - |   |   |   | - |   |   |   | 2,471,050 |   |
| Common stock issued upon conversion of Series C Preferred Stock at $1.50 per share                                   |   |   | - |   |   |   | - |   |   |   | 267,334 |   |   |   | 267 |   |   |   | 400,733 |   |   |   | - |   |   |   | - |   |   |   | 401,000 |   |
| Common stock issued settlement of Series C Preferred Stock accrued dividends at $1.55 per share                      |   |   | - |   |   |   | - |   |   |   | 58,185 |   |   |   | 58 |   |   |   | 90,365 |   |   |   | - |   |   |   | - |   |   |   | 90,423 |   |
| Reclassify fair value of derivative liability to equity upon conversion of Series C Preferred Stock to common shares |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 103,096 |   |   |   | - |   |   |   | - |   |   |   | 103,096 |   |
| Stock based compensation                                                                                             |   |   | - |   |   |   | - |   |   |   | 303,545 |   |   |   | 304 |   |   |   | 3,528,396 |   |   |   | - |   |   |   | - |   |   |   | 3,528,700 |   |
| Preferred Stock dividend                                                                                             |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (110,023 | ) |   |   | - |   |   |   | - |   |   |   | (110,023 | ) |
| Net loss                                                                                                             |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (11,587,187 | ) |   |   | (11,587,187 | ) |
|   Balance, December 31, 2016                                                                               |   |   | - |   |   | $ | - |   |   |   | 22,588,184 |   |   | $ | 22,588 |   |   | $ | 41,019,251 |   |   | $ | - |   |   | $ | (43,829,043 | ) |   | $ | (2,787,204 | ) |

----

Table of Contents

| BIOSIG TECHNOLOGIES, INC.                                                                                              |   |
|------------------------------------------------------------------------------------------------------------------------|--------|
| CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT                                                                     |   |
| TWO YEARS ENDED DECEMBER 31, 2017                                                                                      |   |
|                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   | Additional |   |   | Common |   |   |   |   |   |   |   |
|                                                                                                                   |   | Series D Preferred stock |   |   | Common stock |   |   | Paid in |   |   | stock |   |   | Accumulated |   |   |   |   |
|                                                                                                                   |   | Shares |   |   | Amount |   |   | Shares |   |   | Amount |   |   | Capital |   |   | Subscription |   |   | Deficit |   |   | Total |   |
| Balance, December 31, 2016                                                                                             |   |   | - |   |   | $ | - |   |   |   | 22,588,184 |   |   | $ | 22,588 |   |   | $ | 41,019,251 |   |   | $ | - |   |   | $ | (43,829,043 | ) |   | $ | (2,787,204 | ) |
| Sale of common stock                                                                                                   |   |   | - |   |   |   | - |   |   |   | 4,131,536 |   |   |   | 4,131 |   |   |   | 6,007,098 |   |   |   | - |   |   |   | - |   |   |   | 6,011,229 |   |
| Sale of Series D preferred stock                                                                                       |   |   | 1,334 |   |   |   | 1 |   |   |   | - |   |   |   | - |   |   |   | 1,929,959 |   |   |   | - |   |   |   | - |   |   |   | 1,929,960 |   |
| Common stock issued for services                                                                                       |   |   | - |   |   |   | - |   |   |   | 2,271,788 |   |   |   | 2,272 |   |   |   | 3,384,345 |   |   |   | - |   |   |   | - |   |   |   | 3,386,617 |   |
| Common stock issued upon conversion of Series C Preferred Stock at $1.50 per share                                     |   |   | - |   |   |   | - |   |   |   | 56,669 |   |   |   | 57 |   |   |   | 84,943 |   |   |   | - |   |   |   | - |   |   |   | 85,000 |   |
| Common stock issued settlement of Series C Preferred Stock accrued dividends at $1.37 per share                        |   |   | - |   |   |   | - |   |   |   | 24,021 |   |   |   | 24 |   |   |   | 31,844 |   |   |   | - |   |   |   | - |   |   |   | 31,868 |   |
| Common stock received and canceled in connection with short term swing profit reimbursement                            |   |   | - |   |   |   | - |   |   |   | (10,744 | ) |   |   | (11 | ) |   |   | 11 |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Common stock subscription received                                                                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 29,985 |   |   |   | - |   |   |   | 29,985 |   |
| Reclassify initial fair value of derivative and warrant liability of Series D preferred stock and warrants at issuance |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (1,049,216 | ) |   |   | - |   |   |   | - |   |   |   | (1,049,216 | ) |
| Reclassify fair value of derivative liability to equity upon conversion of Series C Preferred Stock to common shares   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 20,757 |   |   |   | - |   |   |   | - |   |   |   | 20,757 |   |
| Fair value of warrant issued to acquire research and development                                                       |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 543,927 |   |   |   | - |   |   |   | - |   |   |   | 543,927 |   |
| Stock based compensation                                                                                               |   |   | - |   |   |   | - |   |   |   | 259,750 |   |   |   | 260 |   |   |   | 1,362,593 |   |   |   | - |   |   |   | - |   |   |   | 1,362,853 |   |
| Preferred stock dividend                                                                                               |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (119,877 | ) |   |   | - |   |   |   | - |   |   |   | (119,877 | ) |
| Net loss                                                                                                               |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (12,695,743 | ) |   |   | (12,695,743 | ) |
|   Balance, December 31, 2017                                                                                 |   |   | 1,334 |   |   | $ | 1 |   |   |   | 29,321,204 |   |   | $ | 29,321 |   |   | $ | 53,215,635 |   |   | $ | 29,985 |   |   | $ | (56,524,786 | ) |   | $ | (3,249,844 | ) |

----

Table of Contents

| BIOSIG TECHNOLOGIES, INC.                                                                                                 |   |
|---------------------------------------------------------------------------------------------------------------------------|--------|
| STATEMENTS OF CASH FLOWS                                                                                                  |   |
|                                                                                                                      |   |
|                                                                                                                      |   | Year ended December 31, |   |
|                                                                                                                      |   | 2017 |   |   | 2016 |   |
| CASH FLOWS FROM OPERATING ACTIVITIES:                                                                                     |   |   |   |   |   |   |
| Net loss                                                                                                                  |   | $ | (12,695,743 | ) |   | $ | (11,587,187 | ) |
| Adjustments to reconcile net loss to cash used in operating activities:                                                   |   |   |   |   |   |   |   |   |
| Depreciation                                                                                                              |   |   | 11,698 |   |   |   | 10,475 |   |
| Equipment distribution as officer compensation                                                                            |   |   | 3,210 |   |   |   | - |   |
| Change in derivative liabilities                                                                                          |   |   | (210,465 | ) |   |   | 422,908 |   |
| Equity based compensation                                                                                                 |   |   | 4,749,470 |   |   |   | 5,999,750 |   |
| Fair value of issued warrant to acquire research and development                                                          |   |   | 543,927 |   |   |   | - |   |
| Changes in operating assets and liabilities:                                                                              |   |   |   |   |   |   |   |   |
| Prepaid expenses                                                                                                          |   |   | 17,325 |   |   |   | (102,955 | ) |
| Security deposit                                                                                                          |   |   | 10,528 |   |   |   | - |   |
| Accounts payable                                                                                                          |   |   | 102,338 |   |   |   | 149,661 |   |
| Deferred rent payable                                                                                                     |   |   | (2,342 | ) |   |   | (104 | ) |
|   Net cash used in operating activities                                                                         |   |   | (7,470,054 | ) |   |   | (5,107,452 | ) |
|                                                                                                                      |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES:                                                                                     |   |   |   |   |   |   |   |   |
| Purchase of property and equipment                                                                                        |   |   | (9,436 | ) |   |   | (16,255 | ) |
|   Net cash used in investing activity                                                                           |   |   | (9,436 | ) |   |   | (16,255 | ) |
|                                                                                                                      |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES:                                                                                     |   |   |   |   |   |   |   |   |
| Proceeds from sale of common stock                                                                                        |   |   | 6,011,229 |   |   |   | 5,226,368 |   |
| Proceeds from sale of Series D preferred stock                                                                            |   |   | 1,929,960 |   |   |   | - |   |
| Proceeds from common stock subscription                                                                                   |   |   | 29,985 |   |   |   | - |   |
|   Net cash provided by financing activities                                                                     |   |   | 7,971,174 |   |   |   | 5,226,368 |   |
|                                                                                                                      |   |   |   |   |   |   |   |   |
| Net increase in cash and cash equivalents                                                                                 |   |   | 491,684 |   |   |   | 102,661 |   |
|                                                                                                                      |   |   |   |   |   |   |   |   |
| Cash and cash equivalents, beginning of the period                                                                        |   |   | 1,055,895 |   |   |   | 953,234 |   |
| Cash and cash equivalents, end of the period                                                                              |   | $ | 1,547,579 |   |   | $ | 1,055,895 |   |
|                                                                                                                      |   |   |   |   |   |   |   |   |
| Supplemental disclosures of cash flow information:                                                                        |   |   |   |   |   |   |   |   |
| Cash paid during the period for interest                                                                                  |   | $ | - |   |   | $ | - |   |
| Cash paid during the period for income taxes                                                                              |   | $ | - |   |   | $ | - |   |
|                                                                                                                      |   |   |   |   |   |   |   |   |
| Non cash investing and financing activities:                                                                              |   |   |   |   |   |   |   |   |
| Common stock issued upon conversion of Series C Preferred Stock and accrued dividends                                     |   | $ | 116,868 |   |   | $ | 491,423 |   |
| Reclassify initial fair value of derivative and warrant liabilities from equity upon issuance of Series D preferred stock |   | $ | 1,049,216 |   |   | $ | - |   |
| Reclassify fair value of derivative liability to equity                                                                   |   | $ | 20,757 |   |   | $ | 103,096 |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

|                                 |   | 2017   |       |   | 2016   |   |
|--------------------------------------|--------|--------|------------|--------|--------|--------|
| Series C convertible preferred stock |   |   | 656,667    |   |   |   | 713,333 |   |
| Series D convertible preferred stock |   |   | 1,334,000  |   |   |   | - |   |
| Options to purchase common stock     |   |   | 8,510,319  |   |   |   | 8,245,190 |   |
| Warrants to purchase common stock    |   |   | 12,789,086 |   |   |   | 9,128,189 |   |
| Totals                               |   |   | 23,290,072 |   |   |   | 18,086,712 |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|                          |   | 2017   |    |   | 2016   |   |
|-------------------------------|--------|--------|---------|--------|--------|--------|
| Computer equipment            |   | $      | 87,059  |   |   | $      | 84,704 |   |
| Furniture and fixtures        |   |   | 12,975  |   |   |   | 10,117 |   |
| Subtotal                      |   |   | 100,034 |   |   |   | 94,821 |   |
| Less accumulated depreciation |   |   | (81,318 | )      |   |   | (70,633 | ) |
| Property and equipment, net   |   | $      | 18,716  |   |   | $      | 24,188 |   |
|                                      |   | 2017   |    |   | 2016   |   |
|-------------------------------------------|--------|--------|---------|--------|--------|--------|
| Accrued accounting and legal              |   | $      | 93,595  |   |   | $      | 120,464 |   |
| Accrued reimbursements                    |   |   | 2,600   |   |   |   | 43,116 |   |
| Accrued consulting                        |   |   | 109,059 |   |   |   | 1,192 |   |
| Accrued research and development expenses |   |   | 246,030 |   |   |   | 181,884 |   |
| Accrued office and other                  |   |   | 7,912   |   |   |   | 10,202 |   |
| Deferred rent                             |   |   | 569     |   |   |   | 2,912 |   |
| Accrued settlement related to arbitration |   |   | 13,333  |   |   |   | 13,333 |   |
|                                      |   | $      | 473,098 |   |   | $      | 373,103 |   |

----

Table of Contents

|  ● | incur additional indebtedness;                                                                   |
|---------------|--------------------------------------------------------------------------------------------------|
| ●       | permit liens on assets;                                                                          |
| ●       | repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock; |
| ●       | pay cash dividends to our stockholders; and                                                      |
| ●       | engage in transactions with affiliates.                                                          |
|   (i)   | we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,                                                                                                                                                                                                                                                                                                             |
|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (ii)              | we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,                                                                                                                                                                                                                                                                                      |
| (iii)             | we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock,                                                                                                                                                                                                                                                                                                                                                                      |
|  (iv)        | we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered, |
| (v)               | we are party to a change of control transaction,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| (vi)              | we file for bankruptcy or a similar arrangement or are adjudicated insolvent,                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| (vii)             | we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,                                                                                                                                                                                                                                                                                                                                     |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Options Outstanding |      |   | Options Exercisable |   |
|---------------------|-----------|--------|---------------------|--------|
|                |      |   |                |   |   | Weighted |   |   |   |   |
|                |      |   |                |   |   | Average |   |   | Exercisable |   |
| Exercise            |      |   | Number of           |   |   | Remaining Life |   |   | Number of |   |
| Price               |      |   | Options             |   |   | In Years |   |   | Options |   |
| $                   | 1.01-2.00 |   |                |   | 3,825,540 |   |   |   | 6.8 |   |   | $ | 2,662,707 |   |
|                | 2.01-3.00 |   |                |   | 4,384,779 |   |   |   | 3.7 |   |   |   | 4,384,779 |   |
|                | 3.01-4.00 |   |                |   | 300,000 |   |   |   | 7.3 |   |   |   | 300,000 |   |
|                |      |   |                |   | 8,510,319 |   |   |   | 5.2 |   |   |   | 7,347,486 |   |
|                             |   |   |       |   |             |   |   | Weighted-Average |   |   |            |   |
|----------------------------------|--------|--------|------------|--------|------------------|--------|--------|------------------|--------|--------|-----------------|--------|
|                             |   |   |       |   | Weighted-Average |   |   | Remaining        |   |   | Aggregate       |   |
|                             |   | Shares |       |   | Exercise Price   |   |   | Contractual Term |   |   | Intrinsic Value |   |
| Outstanding at January 1, 2016   |   |   | 7,780,190  |   |             | $      | 2.30   |             |   |   | 6.4             |   |   | $ | - |   |
| Grants                           |   |   | 905,000    |   |             |   | 1.71   |             |   |   | 10.0            |   |   | $ | - |   |
| Exercised                        |   |   | -          |   |             |   |   |             |   |   | -               |   |   |   | - |   |
| Canceled                         |   |   | (440,000   | )      |             |   | 2.24   |             |   |   |            |   |   |   | - |   |
| Outstanding at December 31, 2016 |   |   | 8,245,190  |   |             | $      | 2.24   |             |   |   | 5.7             |   |   | $ | - |   |
| Grants                           |   |   | 1,680,898  |   |             |   | 1.50   |             |   |   | 10.0            |   |   | $ | - |   |
| Exercised                        |   |   | -          |   |             |   |   |             |   |   |            |   |   |   |   |   |
| Canceled                         |   |   | (1,415,769 | )      |             | $      | 2.17   |             |   |   |            |   |   |   |   |   |
| Outstanding at December 31, 2017 |   |   | 8,510,319  |   |             | $      | 2.11   |             |   |   | 5.2             |   |   | $ | 27,045 |   |
| Exercisable at December 31, 2017 |   |   | 7,347,486  |   |             | $      | 2.19   |             |   |   | 4.8             |   |   | $ | 25,394 |   |

----

Table of Contents

|                                   |               |   |             |   |
|----------------------------------------|--------------------|--------|------------------|--------|
| Risk-free interest rate                |               |   | 1.08% - 2.04     | %      |
| Dividend yield                         |               |   | 0                | %      |
| Stock price volatility                 |               |   | 109.3% to 122.82 | %      |
| Expected life                          | 5 – 10 years |   |
| Weighted average grant date fair value |               | $      | 1.47             |   |

----

Table of Contents

|                                   |               |   |             |   |
|----------------------------------------|--------------------|--------|------------------|--------|
| Risk-free interest rate                |               |   | 2.01% - 2.34     | %      |
| Dividend yield                         |               |   | 0                | %      |
| Stock price volatility                 |               |   | 95.72% to 107.17 | %      |
| Expected life                          | 5 – 10 years |   |
| Weighted average grant date fair value |               | $      | 1.17             |   |
| Restricted shares issued as of January 1, 2016         |   |   | 175,000  |   |
|--------------------------------------------------------|--------|--------|----------|--------|
| Granted                                                |   |   | 180,000  |   |
| Vested                                                 |   |   | (220,000 | )      |
| Total restricted shares issued as of December 31, 2016 |   |   | 135,000  |   |
| Granted                                                |   |   | -        |   |
| Vested                                                 |   |   | (135,000 | )      |
| Vested restricted shares as of December 31, 2017       |   |   | -        |   |
| Unvested restricted shares as of December 31, 2017     |   |   | -        |   |

----

Table of Contents

| Exercise |   |   | Number      |   | Expiration |
|----------|--------|--------|-------------|--------|------------|
| Price    |   |   | Outstanding |   | Date       |
| $        | 0.001  |   |        |   | 383,320    |   | January 2020 |
| $        | 1.50   |   |        |   | 8,667,440  |   | February 2018 to May 2021 |
| $        | 1.84   |   |        |   | 35,076     |   | January 2020 |
| $        | 1.95   |   |        |   | 1,689,026  |   | October 2018 to September 2019 |
| $        | 2.00   |   |        |   | 100,000    |   | August 2018 |
| $        | 2.02   |   |        |   | 30,755     |   | January 2020 |
| $        | 2.50   |   |        |   | 100,000    |   | August 2018 |
| $        | 2.75   |   |        |   | 228,720    |   | August 2019 to September 2019 |
| $        | 3.67   |   |        |   | 214,193    |   | December 2018 to January 2019 |
| $        | 3.75   |   |        |   | 1,340,556  |   | April 2019 to March 2020 |
|     |   |   |        |   | 12,789,086 |   |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

|                                             |   |   |       |   |             |   |   | Weighted-Average |   |   |            |   |
|--------------------------------------------------|--------|--------|------------|--------|------------------|--------|--------|------------------|--------|--------|-----------------|--------|
|                                             |   |   |       |   | Weighted-Average |   |   | Remaining        |   |   | Aggregate       |   |
|                                             |   | Shares |       |   | Exercise Price   |   |   | Contractual Term |   |   | Intrinsic Value |   |
| Outstanding at January 1, 2016                   |   |   | 7,078,685  |   |             | $      | 2.02   |             |   |   | 3.0             |   |   |   | 497,933 |   |
| Grants                                           |   |   | 2,049,504  |   |             | $      | 1.74   |             |   |   | 2.5             |   |   |   | - |   |
| Exercised                                        |   |   | -          |   |             |   |   |             |   | $      | -               |   |   |   | - |   |
| Canceled                                         |   |   | -          |   |             |   |   |             |   | $      | -               |   |   |   | - |   |
| Outstanding at December 31, 2016                 |   |   | 9,128,189  |   |             | $      | 1.96   |             |   |   | 2.1             |   |   | $ | 494,099 |   |
| Grants                                           |   |   | 4,479,974  |   |             |   | 1.50   |             |   |   | 3.0             |   |   |   | - |   |
| Exercised                                        |   |   | -          |   |             |   |   |             |   |   |            |   |   |   |   |   |
| Canceled                                         |   |   | (819,077   | )      |             | $      | 1.50   |             |   |   |            |   |   |   |   |   |
| Outstanding at December 31, 2017                 |   |   | 12,789,086 |   |             | $      | 1.82   |             |   |   | 1.7             |   |   | $ | 551,636 |   |
|                                             |   |   |       |   |             |   |   |             |   |   |            |   |   |   |   |   |
| Vested and expected to vest at December 31, 2017 |   |   | 12,789,086 |   |             | $      | 1.82   |             |   |   | 1.7             |   |   | $ | 551,636 |   |
| Exercisable at December 31, 2017                 |   |   | 12,789,086 |   |             | $      | 1.82   |             |   |   | 1.7             |   |   | $ | 551,636 |   |

----

Table of Contents

|                                                                                             |   | WarrantLiability |      |   | Derivative |   |
|--------------------------------------------------------------------------------------------------|--------|------------------|-----------|--------|------------|--------|
| Balance, December 31, 2015                                                                       |   | $                | 1,621,199 |   |       | $      | 285,157 |   |
| Total (gains) losses                                                                             |   |             |      |   |       |   |   |   |
| Transfers out due to conversion of Series C Preferred Stock                                      |   |             | -         |   |       |   | (103,096 | ) |
| Mark to market to December 31, 2016                                                              |   |             | 316,035   |   |       |   | 106,873 |   |
| Balance, December 31, 2016                                                                       |   |             | 1,937,234 |   |       |   | 288,934 |   |
| Initial fair value of derivative at date of issuance of Series D Preferred Stock                 |   |             | -         |   |       |   | 397,162 |   |
| Initial fair value of warrant liability at date of issuance                                      |   |             | 652,054   |   |       |   | - |   |
| Transfers out due to conversion of Series C Preferred Stock                                      |   |             | -         |   |       |   | (20,757 | ) |
| Mark to market to December 31, 2017                                                              |   |             | (231,048  | )      |       |   | 20,583 |   |
| Balance, December 31, 2017                                                                       |   |             | 2,358,240 |   |       |   | 685,922 |   |
| Gain (loss) on change in warrant and derivative liabilities for the year ended December 31, 2016 |   | $                | 231,048   |   |       | $      | (20,583 | ) |

----

Table of Contents

| Year Ending December 31, |   |   |    |
|--------------------------|--------|--------|---------|
| 2018                     |   | $      | 112,994 |   |
| 2019                     |   |   | 76,995  |   |
|                     |   | $      | 189,989 |   |

----

Table of Contents

----

Table of Contents

|                                                      |   | 2017   |   |   | 2016   |   |
|-----------------------------------------------------------|--------|--------|--------|--------|--------|--------|
| Statutory rate on pre-tax book loss                  |   |   | (34.00 | )%     |   |   | (34.00 | )% |
| (Gain) loss on change in fair value of derivatives        |   |   | (0.56  | )%     |   |   | 1.24 | % |
| Stock based compensation                                  |   |   | 12.72  | %      |   |   | 17.6 | % |
| Fair value of warrant to acquire research and development |   |   | 1.46   | %      |   |   | 0.00 | % |
| Other                                                     |   |   | 0.09   | %      |   |   | 0.09 | % |
| Valuation allowance                                       |   |   | 20.29  | %      |   |   | 15.07 | % |
|                                                      |   |   | 0.00   | %      |   |   | 0.00 | % |
|                                     |   | 2017   |       |   | 2016   |   |
|------------------------------------------|--------|--------|------------|--------|--------|--------|
| Non-Current deferred tax asset:          |   |   |       |   |   |   |
|  Net operating loss carry-forwards  |   | $      | 8,200,000  |   |   | $      | 5,500,000 |   |
|  Valuation allowance                |   |   | (8,200,000 | )      |   |   | (5,500,000 | ) |
|  Net non-current deferred tax asset |   | $      | -          |   |   | $      | - |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

| 1.   | pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.   | provide reasonable assurance that the transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with the authorization of management and/or of our Board of Directors; and |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.   | provide reasonable assurance regarding the prevention or timely detection of any unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements, including controls related to Section 16 (a) of the Securities Exchange Act of 1934. As disclosed in Section 16 (a), the Company’s Executive Chairman and Director failed to file 125 Form 4 filings for approximately 292 transactions in shares of our common stock executed on various dates between January 1, 2016 and February 28, 2017. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

| Name                            |   | Age |   | Position with the Company                                |
|---------------------------------|--------|-----|--------|----------------------------------------------------------|
| Kenneth L. Londoner             |   | 50  |   | Chief Executive Officer, Executive Chairman and Director |
| Steve Chaussy                   |   | 63  |   | Chief Financial Officer                                  |
| Donald E. Foley                 |   | 66  |   | Director                                                 |
| Roy T. Tanaka                   |   | 69  |   | Director                                                 |
| Andrew L. Filler                |   | 51  |   | Director                                                 |
| Patrick J. Gallagher            |   | 53  |   | Director                                                 |
| Seth H. Z. Fischer              |   | 61  |   | Director                                                 |
| Jeffrey F. O’Donnell, Sr. |   | 58  |   | Director                                                 |
| David Weild IV                  |   | 61  |   | Director                                                 |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Name and principal position                                                            |   | Year |   | Salary($) |    | Bonus($) |   | Stock Awards($) (1) |   |   | OptionAwards ($) |   |   | Nonequity Incentive Plan Compensation ($) |   | Change in Pension Value and Nonqualified Deferred Compensation Earnings ($) |   | All OtherCompensation($) |   | Total($) |   |
|----------------------------------------------------------------------------------------|--------|------|--------|-----------|---------|----------|--------|---------------------|--------|--------|------------------|--------|--------|-------------------------------------------|--------|-----------------------------------------------------------------------------|--------|--------------------------|--------|----------|--------|
| Kenneth L. Londoner, Chief Executive Officer, Executive Chairman and Director (7) |   | 2017 |   |      | 435,000 |     |   | -                   |   |   | 758,500          |   |   |                                      | (1     | )                                                                           |   |                     | -      |     |   | - |   |   | - |   |   | 1,193,500 |   |
|                                                                                        |   | 2016 |   |      | 315,000 |     |   | -                   |   |   | 538,940          |   |   |                                      | (2     | )                                                                           |   |                     | -      |     |   | - |   |   | - |   |   | 853,940 |   |
| Gregory D. Cash, President, Former Chief Executive Officer and Director                |   | 2017 |   |      | 179,252 |     |   |                |   |   | 137,000          |   |   |                                      | (3     | )                                                                           |   |                     | -      |     |   | - |   |   | - |   |   | 316,252 |   |
|                                                                                        |   | 2016 |   |      | 325,000 |     |   |                |   |   | 259,221          |   |   |                                      | (4     | )                                                                           |   |                     | -      |     |   | - |   |   | - |   |   | 584,221 |   |
| Steven Chaussy, Chief Financial Officer                                                |   | 2017 |   |      | 180,833 |     |   |                |   |   | 380,000          |   |   |                                      | (5     | )                                                                           |   |                     | -      |     |   | - |   |   | - |   |   | 560,833 |   |
|                                                                                        |   | 2016 |   |      | 110,000 |     |   |                |   |   | 386,000          |   |   |                                      | (6     | )                                                                           |   |                     | -      |     |   | - |   |   | - |   |   | 496,000 |   |

| (1) | Represents (i) common stock award or 450,000 shares granted November 8, 2017 and (ii) a common stock award of 50,000 shares granted on November 9, 2017                                                                        |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Represents (i) a common stock award of 250,000 shares granted May 4, 2016 and (ii) a common stock award of 41,500 shares granted December 8, 2016.                                                                             |
| (3) | Represents a common stock award of 100,000 shares granted June 6, 2017                                                                                                                                                         |
| (4) | Represents (i) a stock option granted May 18, 2016 for the purchase of 150,000 shares of common stock at $1.84 for ten years, exercisable immediately and (ii) a common stock award of 20,875 shares granted December 8, 2016. |
| (5) | Represents a common stock award of 250,000 shares granted November 8, 2017                                                                                                                                                     |
| (6) | Represents a common stock award of 200,000 shares granted May 4, 2016.                                                                                                                                                         |
| (7) | Mr. Londoner served as our Executive Chairman and Director through the entirety of our last two fiscal years.  Mr. Londoner has served as our Chief Executive Officer since July 31, 2017.                           |

----

Table of Contents

----

Table of Contents

| Name     |   | Number of Securities underlying Unexercised Options (#) Exercisable |    | Number of Securities underlying Unexercised Options (#) Unexercisable |   |   | Option Exercise Price ($/Sh) |   | Option Expiration Date |   | Number of Shares or Units of Stock that have not Vested (#) |      |   | Market Value of Shares of Units That Have Not Vested ($) |   |   | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that Have Not Vested (#) |   |   | Equity Incentive Plan Awards: Market of Payout Value of Unearned Shares, Units or Other Rights that Have Not Vested ($) |   |
|----------|--------|---------------------------------------------------------------------|---------|-----------------------------------------------------------------------|--------|--------|------------------------------|--------|------------------------|--------|-------------------------------------------------------------|-----------|--------|----------------------------------------------------------|--------|--------|---------------------------------------------------------------------------------------------------------|--------|--------|-------------------------------------------------------------------------------------------------------------------------|--------|
| Kenneth  |   |                                                                | 250,000 |                                                                  |   | -      |                         |   | $                      | 2.09   |                                                        | 1/16/2020 |   |                                                     | -      |   |                                                                                                    | $      | -      |                                                                                                                    |   |   | - |   |   | $ | - |   |
| Londoner |   |                                                                |    |                                                                  |   |   |                         |   |                   |   |                                                        |      |   |                                                     |   |   |                                                                                                    |   |   |                                                                                                                    |   |   |   |   |   |   |   |   |
|     |   |                                                                |    |                                                                  |   |   |                         |   |                   |   |                                                        |      |   |                                                     |   |   |                                                                                                    |   |   |                                                                                                                    |   |   |   |   |   |   |   |   |
| Steven   |   |                                                                | 30,000  |                                                                  |   | -      |                         |   | $                      | 2.09   |                                                        | 1/16/2020 |   |                                                     | -      |   |                                                                                                    | $      | -      |                                                                                                                    |   |   | - |   |   | $ | - |   |
| Chaussy  |   |                                                                | 30,000  |                                                                  |   | -      |                         |   | $                      | 2.09   |                                                        | 6/11/2023 |   |                                                     | -      |   |                                                                                                    | $      | -      |                                                                                                                    |   |   | - |   |   | $ | - |   |

----

Table of Contents

| Name                                 |   | Fees Earnedor Paid inCash ($) |   |   | EquityAwards ($) |   |    | Total ($)       |   |
|--------------------------------------|--------|-------------------------------|--------|--------|------------------|--------|---------|-----------------|--------|
| Donald E. Foley                      |   | $                             | -      |   |             | $      | 44,700  |   (1)      |   | $ | 44,700 |   |
| Roy T. Tanaka                        |   | $                             | -      |   |             | $      | 44,700  |   (1) |   | $ | 44,700 |   |
| Andrew L. Filler                     |   | $                             | -      |   |             | $      | 44,700  |   (1) |   | $ | 44,700 |   |
| Patrick J Gallagher                  |   | $                             | -      |   |             | $      | 42,084  |   (2) |   | $ | 42,084 |   |
| Seth H. Z. Fischer                   |   | $                             |   |   |             | $      | 69,537  |   (3) |   | $ | 69,537 |   |
| Jeffrey F O’Donnell, Sr        |   | $                             | -      |   |             | $      | 378,500 |   (4) |   | $ | 378,500 |   |
| David Weild, IV                      |   | $                             | -      |   |             | $      | 74,500  |   (5) |   | $ | 74,500 |   |
| Jerome B. Zeldis (former member) (6) |   | $                             | -      |   |             | $      | -       |            |   | $ | - |   |
| Total:                               |   | $                             | -      |   |             | $      | 698,721 |            |   | $ | 698,721 |   |

| (1) | Represents (i) a common stock award of 30,000 shares granted November 9, 2017                                                                                                                                                       |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Represents (i) a stock option granted December 22, 2017 for the purchase of 39,926 shares of common stock, vesting immediately, at an exercise price of $1.37 per share and termination date of December 22, 2027.                  |
| (3) | Represents (i) 2 stock options granted December 22, 2017 for the purchase of an aggregate of 65,972 shares of common stock, vesting immediately, at an exercise price of $1.37 per share and termination date of December 22, 2027. |
| (4) | Represents (i) a common stock award of 200,000 shares granted on November 8, 2017 and (ii) a common stock award of 50,000 shares granted November 9, 2017.                                                                          |
| (5) | Represents (i) a common stock award  of 50,000 shares granted November 9, 2017                                                                                                                                                 |
| (6) | Dr. Zeldis retired as our director on November 9, 2017.                                                                                                                                                                             |

----

Table of Contents

| Plan category                                         |   | Number ofsecurities tobe issueduponexercise ofoutstandingoptions(a) |      |   | Weighted-averageexerciseprice ofoutstandingoptions(b) |   |   | Securities remainingavailable for futureissuance under equitycompensation plans(excluding securitiesreflected in column (a))(c) |   |
|------------------------------------------------------------|--------|---------------------------------------------------------------------|-----------|--------|-------------------------------------------------------|--------|--------|---------------------------------------------------------------------------------------------------------------------------------|--------|
| Equity compensation plans approved by security holders     |   |                                                                | 8,510,319 |   |                                                  | $      | 2.10   |                                                                                                                            |   |   | 1,907,509 |   |
| Equity compensation plans not approved by security holders |   |                                                                | -         |   |                                                  |   | -      |                                                                                                                            |   |   | - |   |
| Total                                                      |   |                                                                | 8,510,319 |   |                                                  | $      | 2.10   |                                                                                                                            |   |   | 1,907,509 |   |

| ● | by each person who is known by us to beneficially own more than 5.0% of our common stock; |
|---------|-------------------------------------------------------------------------------------------|

| ● | by each of our named executive officers and directors; and |
|---------|------------------------------------------------------------|

| ● | by all of our named executive officers and directors as a group. |
|---------|------------------------------------------------------------------|

----

Table of Contents

| Name of Beneficial Owner                                    |   |   | Number of SharesBeneficially Owned (1) |   |   | Percentage of Common Stock Owned (1)(2) |   |
|-------------------------------------------------------------|--------|--------|----------------------------------------|--------|--------|-----------------------------------------|--------|
|                                                        |   |   |                                   |   |   |                                    |   |
| 5% Owners                                                   |   |   |                                   |   |   |                                    |   |
| Lora Mikolaitis                                             |   |   | 3,408,724                              | (3)    |   |                                    | 11.26  | % |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| David Cherry                                                |   |   | 2,358,639                              | (4)    |   |                                    | 7.73   | % |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| Ramachandra Malya                                           |   |   | 1,820,000                              | (5)    |   |                                    | 6.12   | % |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| Alpha Capital Anstalt                                       |   |   | 3,377,356                              | (6)    |   |                                    | 10.62  | % |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| Officers and Directors                                      |   |   |                                   |   |   |                                    |   |   |
| Kenneth L. Londoner                                         |   |   | 4,361,853                              | (7)    |   |                                    | 14.26  | % |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| Roy T. Tanaka                                               |   |   | 974,802                                | (8)    |   |                                    | 3.16   | % |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| Seth H. Z. Fischer                                          |   |   | 616,916                                | (9)    |   |                                    | 2.02   | % |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| Patrick J. Gallagher                                        |   |   | 296,150                                | (10)   |   |                                    | *      |   |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| Jeffrey F. O’Donnell, Sr.                             |   |   | 779,800                                | (11)   |   |                                    | 2.57   | % |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| Steve Chaussy                                               |   |   | 946,687                                | (12)   |   |                                    | 3.15   | % |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| Andrew L. Filler                                            |   |   | 80,000                                 | (13)   |   |                                    | *      |   |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| David Weild IV                                              |   |   | 400,000                                | (14)   |   |                                    | 1.32   | % |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| Donald E. Foley                                             |   |   | 609,166                                | (15)   |   |                                    | 2.01   | % |
|                                                        |   |   |                                   |   |   |                                    |   |   |
| All directors and executive officers as a group (9 persons) |   |   | 9,065,374                              |   |   |                                    | 29.72  | % |

|  | (1) | Shares of common stock beneficially owned and the respective percentages of beneficial ownership of common stock assume the exercise of all options and other securities convertible into common stock beneficially owned by such person or entity currently exercisable or exercisable within 60 days of February 27, 2018, except as otherwise noted. Shares issuable pursuant to the exercise of stock options and other securities convertible into common stock exercisable within 60 days are deemed outstanding and held by the holder of such options or other securities for computing the percentage of outstanding common stock beneficially owned by such person, but are not deemed outstanding for computing the percentage of outstanding common stock beneficially owned by any other person. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (2) | These percentages have been calculated based on 29,998,466 shares of common stock outstanding as of February 27, 2018. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | (3) | Comprised of (i) 43,750 shares of common stock, (ii) options to purchase 287,500 shares of common stock that are currently exercisable or exercisable within 60 days of February 27, 2018, and (iii) 3,077,474 shares of common stock held by Miko Consulting Group, Inc. Lora Mikolaitis has sole voting and dispositive power over the securities held for the account of Miko Consulting Group, Inc. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (4) | Comprised of (i) 10,000 shares of common stock and warrants to purchase 5,000 shares of common stock, (ii) 316,642 shares of common stock and warrants to purchase 158,321 shares of common stock held by Thomas David Cherry as Trustee of Cherry Family Trust, a trust for which David Cherry is deemed the beneficial owner, and (iii) 1,245,784 shares of common stock and warrants to purchase 622,892 shares of common stock held by Cherry Pipes Ltd., David Cherry has sole voting and dispositive power over the securities held for the account of Cherry Pipes Ltd. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (5) | Comprised of (i) 1,280,000 shares of common stock and (ii) warrants to purchase 540,000 shares of common stock. |
|--|-----|-----------------------------------------------------------------------------------------------------------------|

|  | (6) | Konrad Ackermann has sole voting and dispositive power over the securities held for the account of this selling stockholder.  Includes (i) 288,536 shares of common stock issued upon conversion of 220 Series D shares as of February 27, 2018 (ii) 947,000 shares of common stock issuable upon conversion of Series D Preferred Stock, (iii) 349,725 shares of common stock as a make-whole dividend issuable upon the conversion of Series D Preferred Stock, and (iv) 1,792,095 of common stock issuable upon the exercise of warrants. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (7) | Comprised of (i) 762,250 shares of common stock directly held by Mr. Londoner, (ii) 3,019,974 shares of common stock held by Endicott Management Partners, LLC, an entity for which Mr. Londoner is deemed the beneficial owner, (iii) warrants to purchase 329,629 shares of common stock, and (v) options to purchase 250,000 shares of common stock that are currently exercisable. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (8) | Comprised of (i) 80,875 shares of common stock and (ii) options to purchase 893,927 shares of common stock that are currently exercisable. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------|

|  | (9) | Comprised of (i) 25,000 shares of common stock and (ii) options to purchase 591,916 shares of common stock that are currently exercisable or exercisable within 60 days of February 27, 2018. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (10) | Comprised of (i) 45,000 shares of common stock, (ii) options to purchase 239,926 shares of common stock that are currently exercisable or exercisable within 60 days of February 27, 2018, and (iii) warrants to purchase 11,224 shares of common stock. |
|--|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (11) | Comprised of (i) 409,000 shares of common stock and (ii) options to purchase 370,800 shares of common stock that are currently exercisable. |
|--|------|---------------------------------------------------------------------------------------------------------------------------------------------|

|  | (12) | Comprised of (i) 886,687 shares of common stock and (ii) options to purchase 60,000 shares of common stock that are currently exercisable. |
|--|------|--------------------------------------------------------------------------------------------------------------------------------------------|

|  | (13) | Comprised of (i) 30,000 shares of common stock and (ii) options to purchase 50,000 shares of common stock that are currently exercisable. |
|--|------|-------------------------------------------------------------------------------------------------------------------------------------------|

|  | (14) | Comprised of (i) 50,000 shares of common stock and (ii) options to purchase 350,000 shares of common stock that is currently exercisable. |
|--|------|-------------------------------------------------------------------------------------------------------------------------------------------|

|  | (15) | Comprised of (i) 230,000 shares of common stock, (ii) options to purchase 279,166 shares of common stock that are currently exercisable or exercisable within 60 days of February 27, 2018 and (iii) warrants to purchase 100,000 shares of common stock. |
|--|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

| (1)   | Financial Statements |
|-----------------|----------------------|

| Report of Independent Registered Public Accounting Firm                                         |
|-------------------------------------------------------------------------------------------------|
| Consolidated Balance Sheets as of December 31, 2017 and 2016                                    |
| Consolidated Statements of Operations for the years ended December 31, 2017 and 2016            |
| Consolidated Statement of Stockholders’ Deficit for the two years ended December 31, 2017 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2017 and 2016            |
| Notes to Consolidated Financial Statements                                                      |

| (2)   | Financial Statement Schedules |
|-----------------|-------------------------------|

| (3)   | Exhibits |
|-----------------|----------|

| Exhibit No. |   | Description                                                                                                                                                                                                                   |
|-------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1         |   | Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form S-1 filed on July 22, 2013)                                                              |
| 3.2         |   | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.2 to the Form S-1 filed on July 22, 2013)                              |
| 3.3         |   | Certificate of Second Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.3 to the Form S-1 filed on July 22, 2013)                       |
| 3.4         |   | Certificate of Third Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.5 to the Form S-1/A filed on January 21, 2014)                   |
| 3.5         |   | Certificate of Fourth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.6 to the Form S-1/A filed on March 28, 2014)                    |
| 3.6         |   | Certificate of Fifth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on August 21, 2014)                      |
| 3.7         |   | Certificate of Sixth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on November 25, 2016)                    |
| 3.8         |   | Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on November 9, 2017)                                |
| 3.9         |   | Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on February 16, 2018)                               |
| 3.10        |   | Bylaws of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.4 to the Form S-1 filed on July 22, 2013)                                                                                                         |
| 10.1        |   | BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form S-1 filed on July 22, 2013)                                                                                       |
| 10.2        |   | Form of Stock Option Agreement under the 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Form S-1 filed on July 22, 2013)                                                                        |
| 10.3        |   | Securities Purchase Agreement, dated September 19, 2011, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.3 to the Form S-1 filed on July 22, 2013) |
| 10.4        |   | Securities Purchase Agreement, dated December 27, 2011, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.4 to the Form S-1 filed on July 22, 2013)  |
| 10.5        |   | Securities Purchase Agreement, dated February 6, 2013, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.5 to the Form S-1 filed on July 22, 2013)   |
| 10.6        |   | Registration Rights Agreement, dated February 6, 2013, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.6 to the Form S-1 filed on July 22, 2013)   |
| 10.7        |   | Form of Warrant used in connection with February 6, 2013 private placement (incorporated by reference to Exhibit 10.7 to the Form S-1 filed on July 22, 2013)                                                                 |

----

Table of Contents

| 10.8  |                                       | Amendment Agreement No. 1 to Securities Purchase Agreement and Registration Rights Agreement, dated February 25, 2013, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.8 to the Form S-1 filed on July 22, 2013)        |
|-------|--------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.9  |                                       | Amendment Agreement No. 2 to Securities Purchase Agreement, dated April 12, 2013, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.9 to the Form S-1 filed on July 22, 2013)                                             |
| 10.10 |                                       | Amendment Agreement No. 3 to Securities Purchase Agreement and Registration Rights Agreement, dated June 25, 2013, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.10 to the Form S-1 filed on July 22, 2013)           |
| 10.11 |                                       | Office Lease Agreement, dated August 9, 2011, by and between BioSig Technologies, Inc. and Douglas Emmett 1993, LLC (incorporated by reference to Exhibit 10.11 to the Form S-1 filed on July 22, 2013)                                                                                            |
| 10.12 |                                       | Employment Agreement, dated March 1, 2013, by and between BioSig Technologies, Inc. and Kenneth Londoner (incorporated by reference to Exhibit 10.12 to the Form S-1 filed on July 22, 2013)                                                                                                       |
| 10.13 |                                       | Indemnity Agreement, dated May 2, 2013 by and between BioSig Technologies, Inc. and Seth H. Z. Fischer (incorporated by reference to Exhibit 10.14 to the Form S-1 filed on July 22, 2013)                                                                                                         |
| 10.14 |                             | Amendment Agreement No. 4 to Securities Purchase Agreement, dated October 14, 2013, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.23 to the Form S-1/A filed on January 21, 2014)                                     |
| 10.15 |                             | Securities Purchase Agreement, dated December 31, 2013, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.24 to the Form S-1/A filed on January 21, 2014).                                                                |
| 10.16 |                             | Registration Rights Agreement, dated December 31, 2013, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.25 to the Form S-1/A filed on January 21, 2014)                                                                 |
| 10.17 |                             | Form of Warrant used in connection with December 31, 2013 private placement (incorporated by reference to Exhibit 10.26 to the Form S-1/A filed on January 21, 2014)                                                                                                                               |
| 10.18 |                             | Amendment No. 1 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.27 to the Form S-1/A filed on March 28, 2014)                                                                                                                                 |
| 10.19 |                             | Amendment Agreement No. 5 to Securities Purchase Agreement, dated March 24, 2014, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.28 to the Form S-1/A filed on March 28, 2014)                                         |
| 10.20 |                             | Patent Assignment, dated March 17, 2014, by and among Budimir Drakulic, Thomas Foxall, Sina Fakhar and Branislav Vlajinic and BioSig Technologies, Inc. (incorporated by reference to Exhibit 10.29 to the Form S-1/A filed on May 1, 2014)                                                        |
| 10.21 |                             | Securities Purchase Agreement, dated April 4, 2014, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.30 to the Form S-1/A filed on May 1, 2014)                                                                          |
| 10.22 |                             | Registration Rights Agreement, dated April 4, 2014, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.31 to the Form S-1/A filed on May 1, 2014)                                                                          |
| 10.23 |                             | Form of Warrant used in connection with April 4, 2014 private placement (incorporated by reference to Exhibit 10.32 to the Form S-1/A filed on May 1, 2014)                                                                                                                                        |
| 10.24 |                        | Executive Employment Agreement, dated July 15, 2014, by and between BioSig Technologies, Inc. and Gregory Cash (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on July 21, 2014)                                                                                                  |
| 10.25 |                   | Securities Purchase Agreement, dated as of August 15, 2014, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on August 21, 2014)                                                                 |
| 10.26 |                   | Registration Rights Agreement, dated as of August 15, 2014, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.3 to the Form 8-K filed on August 21, 2014)                                                                 |
| 10.27 |                   | Form of Warrant used in connection with August 15, 2014 private placement (incorporated by reference to Exhibit 10.2 to the Form 8-K filed on August 21, 2014)                                                                                                                                     |
| 10.28 |              | Form of Restricted Stock Award Agreement under the 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Form 8-K filed on September 5, 2014)                                                                                                                               |
| 10.29 |         | Composite of Unit Purchase Agreement, dated December 19, 2014, as amended by Supplement No. 1, dated December 17, 2014, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.37 to the Form 10-K filed on February 20, 2015) |
| 10.30 |         | Registration Rights Agreement, dated December 19, 2014, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.38 to the Form 10-K filed on February 20, 2015)                                                                 |
| 10.31 |         | Form of “B” Warrant used in connection with December 19, 2014 private placement (incorporated by reference to Exhibit 10.40 to the Form 10-K filed on February 20, 2015)                                                                                                               |
| 10.32 |         | Amendment No. 2 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to the Form S-8 filed on April 17, 2015)                                                                                                                                    |
| 10.33 |         | Amendment No. 3 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.41 to the Form S-1 filed on May 20, 2015)                                                                                                                                     |
| 10.34 |         | Securities Purchase Agreement, dated as of May 11, 2015, by and between BioSig Technologies, Inc. and Alpha Capital Anstalt (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on May 15, 2015)                                                                                      |

----

Table of Contents

| 10.35 |         | Securities Purchase Agreement, dated as of May 11, 2015, by and between BioSig Technologies, Inc. and Brio Capital Master Fund Ltd. (incorporated by reference to Exhibit 10.2 to the Form 8-K filed on May 15, 2015)                                                              |
|-------|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.36 |         | Amendment Agreement No. 6 to Securities Purchase Agreement, dated July 30, 2014, by and between BioSig Technologies, Inc. and certain purchasers (incorporated by reference to Exhibit 10.44 to the Form S-1/A filed on June 10, 2015)                                             |
| 10.37 |         | Amendment No. 4 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Form 8-K filed on May 29, 2015)                                                                                                                      |
| 10.38 |         | Form of Subscription Agreement (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on October 29, 2015)                                                                                                                                                               |
| 10.39 |         | Unit Purchase Agreement, dated October 23, 2015, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.2 to the Form 8-K filed on October 29, 2015)                                                           |
| 10.40 |         | Form of Warrant used in connection with October 23, 2015 private placement (incorporated by reference to Exhibit 10.3 to the Form 8-K filed on Form 8-K on October 29, 2015)                                                                                                       |
| 10.41 |         | Registration Rights Agreement, dated October 23, 2015, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.04 to the Form 8-K filed on October 29, 2015)                                                    |
| 10.42 |         | Form of Subscription Agreement (incorporated by reference to the Item 1.01 – Entry Into a Material Definitive Agreement to the Form 8-K filed on November 3, 2016)                                                                                                           |
| 10.43 |         | Unit Purchase Agreement, dated October 28, 2016, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to the Item 1.01 – Entry Into a Material Definitive Agreement to the Form 8-K filed on November 3, 2016)       |
| 10.44 |         | Form of Warrant used in connection with October 28, 2016 private placement (incorporated by reference to the Item 1.01 – Entry Into a Material Definitive Agreement to the Form 8-K filed on November 3, 2016)                                                               |
| 10.45 |         | Registration Rights Agreement, dated October 28, 2016, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to the Item 1.01 – Entry Into a Material Definitive Agreement to the Form 8-K filed on November 3, 2016) |
| 10.46 |         | Amendment No. 5 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on November 25, 2016)                                                                                                                 |
| 10.47 |         | General Release and Severance Agreement, dated May 31, 2017, by and between BioSig Technologies, Inc. and Greg Cash (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on June 2, 2017)                                                                              |
| 10.48 |         | Restricted Stock Award Agreement, dated May 31, 2017, by and between BioSig Technologies, Inc. and Greg Cash (incorporated by reference to Exhibit 10.2 to the Form 8-K filed on June 2, 2017)                                                                                     |
| 10.49 |         | Form of Unit Purchase Agreement, dated April 6, 2016, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.61 to the Form S-1/A filed on August 3, 2017)                                                     |
| 10.50 |         | Form of Warrant used in connection with April 6, 2017 private placement (incorporated by reference to Exhibit 10.62 to the Form S-1/A filed on August 3, 2017)                                                                                                                |
| 10.51 |         | Form of Registration Rights Agreement, dated April 6, 2017, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.63 to the Form S-1/A filed on August 3, 2017)                                               |
| 10.52 |              | Certificate of Designation of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on November 9, 2017)                                                                                                                                |
| 10.53 |              | Form of Securities Purchase Agreement dated November 3, 2017, by and between BioSig Technologies, Inc. and certain accredited investors (incorporated by reference to Exhibit 10.1 to Form 8-K filed on November 9, 2017)                                                          |
| 10.54 |                   | Form of Warrant A used in connection with November 3, 2017 sale of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 10.2 to Form 8-K filed on November 9, 2017                                                                                           |
| 10.55 |                        | Form of Warrant B used in connection with November 3, 2017 sale of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 10.3 to Form 8-K filed on November 9, 2017                                                                                           |
| 10.56 |                             | Form of Registration Rights Agreement dated November 3, 2017, by and between BioSig Technologies, Inc. and certain purchasers of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 10.4 to Form 8-K filed on November 9, 2017                             |
| 10.57 |                                  | Form of Securities Purchase Agreement dated February 16, 2018, by and between BioSig Technologies, Inc. and certain accredited investors (incorporated by reference to Exhibit 10.1 to Form 8-K filed on February 16, 2018)                                                        |
| 10.58 |                                       | Form of Warrant used in connection with February 16, 2018 sale of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 10.2 to Form 8-K filed on February 16, 2018)                                                                                          |
| 10.59 |                                       | Form of Registration Rights Agreement dated February 16, 2018, by and between BioSig Technologies, Inc. and certain purchasers of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 10.3 to Form 8-K filed on February 16, 2018)                          |

----

Table of Contents

| 31.01     |   | Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.               |
|-----------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|      |   |                                                                                                                                                                                 |
| 31.02     |   | Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.               |
|      |   |                                                                                                                                                                                 |
| 32.01     |   | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|      |   |                                                                                                                                                                                 |
| 101 INS * |   | XBRL Instance Document                                                                                                                                                               |
|      |   |                                                                                                                                                                                 |
| 101 SCH * |   | XBRL Taxonomy Extension Schema Document                                                                                                                                              |
|      |   |                                                                                                                                                                                 |
| 101 CAL * |   | XBRL Taxonomy Calculation Linkbase Document                                                                                                                                          |
|      |   |                                                                                                                                                                                 |
| 101 LAB * |   | XBRL Taxonomy Labels Linkbase Document                                                                                                                                               |
|      |   |                                                                                                                                                                                 |
| 101 PRE * |   | XBRL Taxonomy Presentation Linkbase Document                                                                                                                                         |
|      |   |                                                                                                                                                                                 |
| 101 DEF * |   | XBRL Taxonomy Extension Definition Linkbase Document                                                                                                                                 |

----

Table of Contents

----

Table of Contents

|                 | BIOSIG TECHNOLOGIES, INC. |                                                                                   |
|----------------------|---------------------------|----------------------------------------------------------------------------------------|
|                 |                      |                                                                                   |   |
| Date: March 26, 2018 | By:                       |  /s/ KENNETH L. LONDONER                                                          |   |
|                 |                      | Kenneth L. Londoner                                                                    |   |
|                 |                      | Chief Executive Officer and Executive Chairman (Principal Executive Officer)           |   |
|                 |                      |                                                                                   |   |
| Date: March 26, 2018 | By:                       | /s/ STEVEN CHAUSSY                                                                     |   |
|                 |                      | Steven Chaussy                                                                         |   |
|                 |                      | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |   |

| Name                                |   | Position |   | Date           |
|-------------------------------------|--------|----------|--------|----------------|
|                                |   |     |   |           |
| /s/ DONALD E. FOLEY            |   | Director |   | March 26, 2018 |
| Donald E. Foley                     |   |     |   |           |
|                                |   |     |   |           |
| /s/ ANDREW L. FILLER                |   | Director |   | March 26, 2018 |
| Andrew L. Filler                    |   |     |   |           |
|                                |   |     |   |           |
| /s/ PATRICK J. GALLAGHER            |   | Director |   | March 26, 2018 |
| Patrick J. Gallagher                |   |     |   |           |
|                                |   |     |   |           |
| /s/ ROY T. TANAKA                   |   | Director |   | March 26, 2018 |
| Roy T. Tanaka                       |   |     |   |           |
|                                |   |     |   |           |
| /s/ SETH H. Z. FISCHER              |   | Director |   | March 26, 2018 |
| Seth H. Z. Fischer                  |   |     |   |           |
|                                |   |     |   |           |
| /s/ JEFFREY F. O’DONNELL, SR. |   | Director |   | March 26, 2018 |
| Jeffrey F. O’Donnell, Sr.     |   |     |   |           |
|                                |   |     |   |           |
| /s/ DAVID WEILD IV                  |   | Director |   | March 26, 2018 |
| David Weild IV                      |   |     |   |           |